Brenda Payton v. Abbott Labs, Eli Lilly and Company

780 F.2d 147, 19 Fed. R. Serv. 1077, 1985 U.S. App. LEXIS 25821
CourtCourt of Appeals for the First Circuit
DecidedDecember 27, 1985
Docket85-1247
StatusPublished
Cited by115 cases

This text of 780 F.2d 147 (Brenda Payton v. Abbott Labs, Eli Lilly and Company) is published on Counsel Stack Legal Research, covering Court of Appeals for the First Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Brenda Payton v. Abbott Labs, Eli Lilly and Company, 780 F.2d 147, 19 Fed. R. Serv. 1077, 1985 U.S. App. LEXIS 25821 (1st Cir. 1985).

Opinion

BOWNES, Circuit Judge.

Defendant Eli Lilly and Co. (Lilly) appeals from a judgment below awarding plaintiff Andrea Goldstein $50,000 for injuries she claims were caused by a drug, diethylstilbestrol (DES), ingested by her mother while Andrea was in útero. A separate claim of Mrs. Goldstein’s husband, Paul, for loss of consortium was denied by the jury and no appeal has been taken from it.

In August 1977, Andrea and Paul Gold-stein were added as plaintiffs to the case of Payton v. Abbott Laboratories, which had begun in April 1976. This case was begun as a class action and was conditionally certified, but subsequently the plaintiff class was decertified and the plaintiffs’ suits were separated for individual trials.

The issues are: (1) whether the district court erred in striking one of the jury’s special findings and not ordering a new trial; (2) whether there were inconsistencies in the jury’s answers to interrogatories sufficient to require a new trial; (3) wheth *149 er alleged errors in the jury charge require a new trial; (4) whether the alleged failures of proof on causation and/or proof that defendants manufactured the DES taken by plaintiffs mother require reversal and judgment for the defendant.

I. BACKGROUND

In the early 1950’s, when plaintiff Andrea Goldstein was born, DES was sometimes prescribed according to the Smith & Smith regimen 1 for pregnant women thought to be in danger of miscarriage. Andrea Goldstein’s mother, Mrs. Schwartz, besides having one healthy baby boy also had two miscarriages before becoming pregnant with Andrea. Apparently because of this history of prior miscarriages, Dr. Ko, a resident at the New England Hospital where Mrs. Schwartz was given prenatal care, prescribed the Smith & Smith DES regimen for her beginning in the ninth week of pregnancy. The regimen provided for continually increasing amounts of DES to be taken by the expectant mother, beginning with a daily dose of 5 mg. in the seventh and eighth weeks of pregnancy, and increasing by 5 mg. every other week until the fifteenth week, after which it was increased by 5 mg. each week until the thirty-fifth and final week when the daily dosage was 125 mg. In order to make the daily ingestion of the increasing amounts of the drug easier for the expectant mother, it was recommended that 5 mg. tablets be taken in the seventh through the fourteenth weeks and 25 mg. tablets be taken thereafter. Although Mrs. Schwartz could not remember the brand of DES she took and the original prescription could not be found, she did remember she had had the prescription filled at Trachtenberg & Meyers Pharmacy, and that the first pills she took (the 5 mg. ones) were red and the second ones (the 25 mg. ones) were white.

Andrea was born, an apparently healthy child, in 1953. It was not until the 1970’s when fears began to be publicly expressed that DES might be causing cancer in women exposed to it in útero that Andrea learned that she had been exposed to it while in her mother’s womb. She was examined by a physician for potential DES-related problems and it was discovered that she had certain vaginal abnormalities, one called adenosis and the other a cervical hood, which had been identified as possible precursors to cervical cancer in DES-exposed women. Andrea then began to see a gynecologist regularly so that he could monitor the condition of her reproductive organs and examine any changes for signs of cancer.

In 1976, Andrea became pregnant in her left fallopian tube. This ectopic pregnancy made the removal of the tube necessary. While performing the operation, her physician discovered that Andrea’s remaining fallopian tube and her uterus were deformed. The uterus in particular was very small and oddly shaped. Her physician felt these problems were also related to DES. Desiring to have her own children, Andrea also began seeing a physician specializing in fertility problems. Many tests, internal pelvic examinations, X-rays and an attempt to stretch her uterus followed. In 1978, Andrea had a normal uterine pregnancy, but the pregnancy was aborted within a few weeks due to a miscarriage. More tests, examinations and X-rays followed. In 1980, she became pregnant again, this time in her remaining right fallopian tube. Despite her doctors’ efforts to save it, the tube had to be removed. Both tubal pregnancies caused severe pain. After the second ectopic pregnancy, Andrea became infertile. Her doctor referred her to an in vitro fertilization clinic but said there was very little likelihood her malformed uterus could carry a child to term even if she were to become pregnant by in vitro fertilization.

II. THE POST-TRIAL EVENTS

The case was submitted to the jury as a negligence claim. 2 The issues below were *150 whether Lilly was negligent in marketing DES or in failing to have an adequate warning accompany the drug, whether the white 25 mg. DES tablets were manufactured by Lilly and whether they were the cause or a significant contributing cause of plaintiffs two ectopic pregnancies, uterine miscarriage, malformed uterus and adeno-sis and cervical hood. The trial court made an unchallenged finding that, because of insufficiency of evidence, the jury could not find that the red 5 mg. DES tablets plaintiff’s mother took while she was pregnant with plaintiff were manufactured by Lilly. Liability, therefore, could only be based on the 25 mg. pills. The case went to the jury in the form of special interrogatories pursuant to Federal Rule of Civil Procedure 49(a).

The jury found three injuries, causation and negligence. It awarded damages in the amount of $50,000. The special interrogatories and answers thereto are as follows:

A. Claim of Andrea Goldstein.
1. Was the DES taken by the plaintiff’s mother in 1953 probably a cause of
a. The plaintiff’s left ectopic pregnancy in 1976?
YES
b. The plaintiff’s right ectopic pregnancy in 1980?
NO
c. The miscarriage of the plaintiff’s uterine pregnancy in 1978?
NO
d. Malformation of the plaintiff’s uterus sufficient to interfere with normally carrying a pregnancy to term?
YES
e. Plaintiff’s adenosis and cervical hood?
YES
If the jury has answered “No” to all of the above, that is the end of the case. If the jury has answered “Yes” to any of the above, proceed to question 2.
2. With respect to any injury to the plaintiff found by the jury to have been caused by her mother’s use of DES, is it probable that white 25 mg. DES pills were a contributing cause of such injury?
YES

Free access — add to your briefcase to read the full text and ask questions with AI

Related

FOX v. MAKIN
D. Maine, 2025
Algarin-Moure v. Baez-Lopez
D. Puerto Rico, 2023
Pritt v. John Crane, Inc.
D. Massachusetts, 2022
Blackjewel, L.L.C. v. United Bank
S.D. West Virginia, 2022
Martinez v. United States
33 F.4th 20 (First Circuit, 2022)
Lawes v. CSA Architects and Engineers
963 F.3d 72 (First Circuit, 2020)
Pukt v. Nexgrill Industries
2016 DNH 085 (D. New Hampshire, 2016)
Irwin v. Eclectic Dining, Inc.
155 F. Supp. 3d 126 (D. Massachusetts, 2016)
United States v. Hughes
44 F. Supp. 3d 169 (D. Massachusetts, 2014)
Morin v. AutoZone Northeast, Inc.
943 N.E.2d 495 (Massachusetts Appeals Court, 2011)
Fernandes v. Havkin
731 F. Supp. 2d 103 (D. Massachusetts, 2010)

Cite This Page — Counsel Stack

Bluebook (online)
780 F.2d 147, 19 Fed. R. Serv. 1077, 1985 U.S. App. LEXIS 25821, Counsel Stack Legal Research, https://law.counselstack.com/opinion/brenda-payton-v-abbott-labs-eli-lilly-and-company-ca1-1985.